检索结果-南通市图书馆

Long-term survival of esophageal squamous cell carcinoma after surgical treatment in a large-scale retrospective study from a single cancer center

引用

Holistic Integrative Oncology 2023年第1期2卷 283-290页

作者： Kunhan Ni Zhiyu Li Kexun Li Changding Li Kunyi Du Xin Nie Kun Liu Kunzhi Li Yixuan huang Simiao Lu Longlin Jiang Wenwu He Chenghao Wang Kangning Wang Qiang Zhou Haojun Li Jialong Li Guangyuan Liu Wenguang Xiao Qiang Fang Lin Peng Qifeng Wang Yongtao Han Xuefeng Leng Department of Thoracic Surgery Sichuan Clinical Research Center for CancerSichuan Cancer Hospital&InstituteSichuan Cancer CenterAffiliated Cancer Hospital of University of Electronic Science and Technology of China(UESTC)ChengduChina Department of Thoracic Surgery the Affiliated Hospital of Southwest Medical UniversityLuzhouSichuanChina Radiation Oncology Key Laboratory of Sichuan Province Department of Radiation OncologySichuan Clinical Research Center for CancerSichuan Cancer Hospital&InstituteSichuan Cancer CenterAffiliated Cancer Hospital of University of Electronic Science and Technology of China(UESTC)ChengduChina

Purpose To analyze the long-term overall survival(OS)and influencing factors of patients with esophageal squamous cell cancer(ESCC)under surgical *** We collected patients with ESCC who received surgical treatment in Sichuan Cancer Hospital&institute from January 2010 to December 2017,and selected 2,766 patients with thoracic esophageal carcinoma with relatively complete follow-up results as the objects of this *** analyzed the characteristics,postoperative complications and long-term OS results of those *** Of the 2766 patients,81.6%were male,midthoracic esophageal cancer accounted for 53.5%.McKeown was used in 72.0%of patients and Ivor-Lewis was used in 26.4%of *** 47.8%of patients received minimally invasive esophagectomy(MIE).The overall complication rate was 25.8%.The 1-year,3-year and 5-year OS rates were 86.2%,57.5%and 46.8%,*** had a better long-term OS rate than Ivor-Lewis(49.5%vs 41.2%,P<0.001),and MIE is superior to open surgery(51.8%vs 42.5%,P<0.001).Conclusion McKeown has advantages over *** results in better long-term survival outcomes for *** more prospective randomized controlled trials with large samples are needed.

关键词： Esophageal squamous cell carcinoma Minimally invasive esophagectomy Open surgery McKeown Ivor-Lewis Overall survival rate

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Current status of diagnosis and treatment of bladder cancer in China-Analyses of Chinese Bladder Cancer Consortium database

引用

Asian Journal of Urology 2015年第2期2卷 63-69页

作者： Kaiwen Li Tianxin Lin 无 Wei Xue Xin Mu Enci Xu Xu Yang Fubao Chen Guangyong Li Lulin Ma Guoliang Wang Chaozhao Liang Haoqiang Shi Ming Li Mao Tang Xueyi Xue Yisong Lv Yaoliang Deng Chengyang Li Zhiwen Chen Xiaozhou Zhou Fengshuo Jin Xudong Liu Jinxin Wei Lei Shi Xin Gou Weiyang He Liqun Zhou Lin Cai Baiye Jin Guanghou Fu Xiangbo Kong Hongyan Sun Ye Tian Lang Feng Tiejun Pan Yiyi Wu Dongwen Wang Hailong Hao Benkang Shi Yaofeng Zhu Qiang Wei Ping Han Changli Wu Dawei Tian Zhangqun Ye Zheng Liu Zhiping Wang Junqiang Tian Lin Qi Minfeng Chen Wei Li Jinchun Qi Gongxian Wang Longlong Fu Zhaolin Sun Guangheng Luo Zhoujun Shen Zhaowei Zhu Jinchun Xing Zhun Wu Dong Wei Xin Chen Yanqun Na Hongfeng Guo Chunxi Wang Zhihua Lu Chuize Kong Yang Liu Jin Yang Jianyun Hu Xin Gao Jielin Li Changjun Yin Pu Li Shan Chen Zhen Du Jiongming Li Yongji Yan Xu Zhang Shuang huang Fangjian Zhou Zhiling Zhang Yinghao Sun Shuxiong Zeng Song Cen Jiaquan Zhou Hanzhong Li Jin Wen Jian huang Department of Urology Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhouChina Chinese Bladder Cancer Consortium Department of Urology Renji HospitalShanghai Jiaotong University School of MedicineShanghaiChina Department of Urology Fujian Medical University Union HospitalFuzhouChina Department of Urology General Hospital of Ningxia Medical UniversityYinchuanChina Department of Urology Peking University Third HospitalBeijingChina Department of Urology The First Affiliated Hospital of Anhui Medical UniversityHefeiChina Department of Urology The Xinjiang Uygur Autonomous Region People’s HospitalUygurChina Department of Urology The First Affiliated Hospital of Fujian Medical UniversityFuzhouChina Department of Urology The First Affiliated Hospital of Guangxi Medical UniversityNanningChina Department of Urology Southwest HospitalThird Military Medical UniversityChongqingChina Department of Urology Daping HospitalThird Military Medical UniversityChongqingChina Department of Urology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina Department of Urology The First Affiliated Hospital of Chongqing Medical UniversityChongqingChina Department of Urology Peking University First HospitalBeijingChina Department of Urology The First Affiliated Hospital of Zhejiang UniversityHangzhouChina Department of Urology China Japan Friendship Hospital of Jilin UniversityChangchunChina Department of Urology Beijing Friendship HospitalCapital Medical UniversityBeijingChina Department of Urology Wuhan General Hospital of Guangzhou MilitaryWuhanChina Department of Urology The First Affiliated Hospital of Shanxi UniversityTaiyuanChina Department of Urology Qilu Hospital of Shandong UniversityJinanChina Department of Urology West China HospitalSichuan UniversityChengduChina Department of Urology The Second Affiliated Hospital of Tianjin Medical UniversityTianjinChina Department of Urology Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Objective:To investigate current status of diagnosis and treatment of bladder cancer in ***:A database was generated by Chinese Bladder Cancer Consortium(CBCC).From January 2007 to December 2012,14,260 cases from 44 CBCC centers were *** of diagnosis,treatment and pathology were ***:The average age was 63.5 year-old and most patients were male(84.3%).The most common histologic types were urothelial carcinoma(91.4%),adenocarcinoma(1.8%),and squamous carcinoma(1.9%).According to 1973 and 2004 WHO grading system,42.0%,41.0%,and 17.0% of patients were grade 1,2,and 3,and 16.0%,48.7%,and 35.3% of patients were papillary urothelial neoplasms of low malignant potential,low,and high grade,***-muscle invasive bladder cancer(NMIBC)and muscle invasive bladder cancer(MIBC)were 25.2% and 74.1%,respectively(0.8% not clear).Carcinoma in situ was only 2.4%.Most patients were diagnosed by white-light cystoscopy with biopsy(74.3%).Fluorescence and narrow band imaging cystoscopy had additional detection rate of 1.0% and 4.0%,*** transurethral resection(TUR)provided detection rate of 16.9%.Most NMIBCs were treated with TUR(89.2%).After initial TUR,2.6%accepted second TUR,and 45.7%,69.9%,and 58.7% accepted immediate,induced,and maintenance chemotherapy instillation,*** MIBCs were treated with radical cystectomy(RC,59.7%).Laparoscopic RCs were 35.1%,while open RC 63.4%.Extended and standard pelvic lymph node dissection were 7% and 66%,*** most common urinary diversions were orthotopic neobladder(44%),ileal conduit(31%),and ureterocutaneostomy(23%).Only 2.3% of patients accepted neo-adjuvant chemotherapy and only 18%of T3 and T4 patients accepted adjuvant ***:Disease characteristics are similar to international reports,while differences of diagnosis and treatment *** study can provide evidences for revisions of the guideline on bladder cancer in China.

关键词： Bladder cancer Diagnosis Treatment

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

输尿管纤维软镜治疗肾结石350例的疗效分析

引用

右江医学 2020年第2期48卷 119-121页

作者：黄华刚周建方唐楠王建伟张璐田景玉李宁枕周哲首钢水钢总医院泌尿外科贵州六盘水553028 北京大学首钢医院吴阶平泌尿外科医学中心北京100041

目的对输尿管纤维软镜治疗肾结石的疗效进行分析总结。方法收集2015年1月至2018年12月使用输尿管纤维软镜联合钬激光治疗的350例肾结石患者的资料,分析患者置鞘成功率、碎石成功率、残石率、手术时间、严重并发症。结果置鞘成功率:24例... 详细信息

目的对输尿管纤维软镜治疗肾结石的疗效进行分析总结。方法收集2015年1月至2018年12月使用输尿管纤维软镜联合钬激光治疗的350例肾结石患者的资料,分析患者置鞘成功率、碎石成功率、残石率、手术时间、严重并发症。结果置鞘成功率:24例预留双J管,二期置鞘成功率100.0%,326例一期置鞘成功率92.9%(303/326),两组比较差异无统计学意义(χ^2=0.845,P=0.358)。碎石成功率:肾上盏结石76例,2例碎石未成功,成功率97.4%;肾盂结石107例、肾中盏结石109例,均碎石成功,成功率100.0%;肾下盏结石58例,6例碎石未成功,成功率89.7%,总的成功率为97.7%。残石率:术后1个月影像学复查,以残石≥4 mm视为残石,19例有残石,占5.4%。手术时间:330例结石1.0~2.0 cm,均顺利完成手术,手术时间30~70 min,平均55 min;20例结石2.1~3.6 cm,手术时间50~140 min,平均85 min。严重并发症:术后尿脓毒血症5例,其中1例死亡。结论输尿管纤维软镜治疗肾结石安全、有效,但有潜在的高危风险,涵盖在置鞘、术后并发症的处理等过程。

关键词：输尿管软镜肾结石钬激光

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

六盘水市泌尿系结石165例成分分析

引用

中国医药科学 2021年第8期11卷 149-151,174页

作者：黄华刚周建方王建伟张璐何俊田景玉李宁枕周哲首钢水钢总医院泌尿外科贵州六盘水553028 北京大学首钢医院吴阶平泌尿医学中心北京100041

目的分析六盘水市泌尿系结石的特点,为结石的治疗和预防复发提供参考依据。方法回顾性分析2018年1月至2019年12月在我科住院六盘水市泌尿系结石患者,共165例,收集患者的一般资料和结石成分,比较患者在年龄、居住地、性别、结石部位、结... 详细信息

目的分析六盘水市泌尿系结石的特点,为结石的治疗和预防复发提供参考依据。方法回顾性分析2018年1月至2019年12月在我科住院六盘水市泌尿系结石患者,共165例,收集患者的一般资料和结石成分,比较患者在年龄、居住地、性别、结石部位、结石成分等方面的差异。结果165例患者中,中年组患者泌尿系结石的检出率最高,为105例(63.6%);中年组与青年组、老年组比较差异有统计学意义(P0.05);男性117例(70.9%),女性48例(29.1%),男性多于女性(P<0.05);上尿路结石153例(92.7%),高于下尿路结石的12例(7.3%),差异有统计学意义(P<0.05)。检出了6种结石成分,包括一水草酸钙、二水草酸钙、碳酸磷灰石、尿酸胺、无水尿酸和L-胱氨酸。结石类型以混合结石为主,共117例(70.9%);其中,最多的是一水草酸钙+碳酸磷灰石39例(23.4%)。结论泌尿系结石患者发病情况中存在一定的年龄、性别及结石部位差异,可根据结石分布特点及成分分析结果,为泌尿系结石的诊治及预防复发提供重要的理论依据。

关键词：泌尿系结石六盘水市红外光谱法结石成分分析

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

索磷布韦/维帕他韦用于基因1-6型HCV中国患者时的安全性和疗效:来自一项3期临床试验的结果

索磷布韦/维帕他韦用于基因1-6型HCV中国患者时的安全性和疗效:来...

引用

第十届全国疑难及重症肝病大会

作者： Lai Wei Qing Xie Yan huang Shanming Wu Min Xu Hong Tang Jun Cheng Yanhang Gao Zhuangbo Mou Xiaoguang Dou Yuemin Nan Qin Ning Yimin Mao Luisa Stamm Sophia Lu Hadas Dvory-Sobol Hongmei Mo Diana Brainard Yongfeng Yang Guiqiang Wang Peng Hu Lunli Zhang Zhiliang Gao Feng Lin Jia Shang Guozhong Gong Jun Li Minghua Su Zhongping Duan Jinlin Hou Jidong Jia Peking University Hepatology Institute Peking University People's Hospital Ruijin Hospital Xiangya Hospital Central South University Shanghai Public Health Center Guangzhou Eighth Municipal People's Hospital West China Hospital of Sichuan University Beijing Ditan Hospital Capital Medical University 1st Hospital of Jilin University Jinan Infectious Disease Hospital Shengjing Hospital of China Medical University The Third Hospital of Hebei Medical University

背景慢性丙型肝炎病毒(HCV)感染在中国仍然是一项主要的卫生问题,累及至少1000万人,而且感染患者中存在多种基因型(GT)(GT1b57%、GT215%、GT39%、GT66%)。迫切需要简单的全口服泛基因型直接作用抗病毒疗法来治疗该地区的HCV。本研究评估...

背景慢性丙型肝炎病毒(HCV)感染在中国仍然是一项主要的卫生问题,累及至少1000万人,而且感染患者中存在多种基因型(GT)(GT1b57%、GT215%、GT39%、GT66%)。迫切需要简单的全口服泛基因型直接作用抗病毒疗法来治疗该地区的HCV。本研究评估了12周的SOF/VEL用于中国患者时的疗效和安全性。方法在一项单臂、开放标签的试验中,无肝硬化或伴有代偿期肝硬化的感染慢性GT1-6HCV

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：